TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15527610

Group type: EXPERIMENTAL
Intervention: General practitioners' knowledge of PTSD management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General practitioners' referral practices for PTSD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Drug treatment knowledge for PTSD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recognition and prescription knowledge for PTSD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Best practice management for PTSD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best practice management for depression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recognition knowledge for depression
Number of subjects: 0
Study: 11207629

Group type: EXPERIMENTAL
Intervention: Ethinyl oestradiol (30 microg, EE2)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Low-dose oral conjugated oestrogen (0.625 mg, CE)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Both EE2 and CE
Number of subjects: 17
Study: 9870553

Group type: EXPERIMENTAL
Intervention: D-alpha-tocopherol 2 g/day
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: L-ascorbic acid 3 g/day
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: D-alpha-tocopherol 2 g/day combined with L-ascorbic acid 3 g/day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 8304606

Group type: EXPERIMENTAL
Intervention: Indomethacin 100-mg rectal suppository
Number of subjects: 51

Group type: COMPARATOR
Intervention: Morphine by IV titration (5-mg loading dose and up to two additional 2.5-mg doses if needed)
Number of subjects: 51
Study: 2471005

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 17

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 17
Study: 31326995

Group type: EXPERIMENTAL
Intervention: EEL-enhanced IVOCT
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard IVOCT
Number of subjects: 200
Study: 30794165

Group type: EXPERIMENTAL
Intervention: Attended condition (self-paced dorsiflexion)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Distracted condition (dual-task with oddball task)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Combination of parietal channels
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Combination of central and parietal channels
Number of subjects: 27
Study: 29197830

Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 1590
Study: 25899652

Group type: COMPARATOR
Intervention: IV phenytoin (PHT) 20mg/kg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: IV levetiracetam (LEV) 20mg/kg
Number of subjects: 44

Group type: COMPARATOR
Intervention: IV phenytoin (PHT)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: IV levetiracetam (LEV)
Number of subjects: 44
Study: 22777834

Group type: EXPERIMENTAL
Intervention: Cediranib (3 mg/kg per dose daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study: 21482957

Group type: EXPERIMENTAL
Intervention: Vandetanib treatment for 6 weeks
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Vandetanib treatment
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: In vitro analyses of cultured endothelial cells with vandetanib
Number of subjects: 17
Study: 18608400

Group type: EXPERIMENTAL
Intervention: Twice-weekly water exercise
Number of subjects: 22

Group type: COMPARATOR
Intervention: Once-weekly water exercise
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both groups (once and twice weekly)
Number of subjects: 22
Study: 16676338

Group type: EXPERIMENTAL
Intervention: Three dietary fibers with different levels of fermentability
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 14581144

Group type: EXPERIMENTAL
Intervention: Insulin Lispro plus lunch and bedtime NPH insulin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Premeal regular insulin plus bedtime NPH insulin
Number of subjects: 60
Study: 11872050

Group type: EXPERIMENTAL
Intervention: Screening with a single ultrasonographic scan
Number of subjects: 9342

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 9342
Study: 9666870

Group type: EXPERIMENTAL
Intervention: High-dose carbimazole (100 mg per day plus thyroxine)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Low-dose carbimazole (starting at 25 mg, titrated)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: High-dose carbimazole
Number of subjects: 37

Group type: COMPARATOR
Intervention: Low-dose carbimazole
Number of subjects: 37
Study: 7664011

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ultrasound surveillance
Number of subjects: 0
Study: 2485286

Group type: EXPERIMENTAL
Intervention: Monetary incentive
Number of subjects: 70

Group type: COMPARATOR
Intervention: No incentive
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Levine Hypothesis Test
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Conceptual Level Analogy Test
Number of subjects: 70
Study: 13969

Group type: EXPERIMENTAL
Intervention: Bromazepam (mean daily dose: 23.8 mg)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Amitriptyline (mean daily dose: 94 mg)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (4.6 capsules)
Number of subjects: 72
Study: 31288004

Group type: EXPERIMENTAL
Intervention: Î²-Cryptoxanthin (0-40 μM)
Number of subjects: 0
Study: 28333252

Group type: EXPERIMENTAL
Intervention: Single-layer plication with continuous 2-0 monofilament nylon suture (group I)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Single-layer plication with continuous barbed suture (group II)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (two-layer plication with 2-0 monofilament nylon suture)
Number of subjects: 30
Study: 25782367

Group type: EXPERIMENTAL
Intervention: Self-reports of medication side effects
Number of subjects: 111

Group type: COMPARATOR
Intervention: Controlling for patient demographics, pain intensity, and negative affect
Number of subjects: 111
Study: 24055444

Group type: EXPERIMENTAL
Intervention: XIENCE V everolimus-eluting stent (EES)
Number of subjects: 600

Group type: COMPARATOR
Intervention: TAXUS paclitaxel-eluting stent (PES)
Number of subjects: 600
Study: 22085126

Group type: EXPERIMENTAL
Intervention: Immediate insertion of topical lignocaine gel
Number of subjects: 50

Group type: COMPARATOR
Intervention: 3‐min delay after lubrication with topical lignocaine gel
Number of subjects: 50
Study: 19757875

Group type: EXPERIMENTAL
Intervention: Developmentally appropriate music listening intervention
Number of subjects: 24

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 24
Study: 17001224

Group type: EXPERIMENTAL
Intervention: Moderate exercise training program at 60% of peak VO2 three times a week for 8 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (avoided physical training)
Number of subjects: 52
Study: 15542277

Group type: EXPERIMENTAL
Intervention: MO.MA system (Invatec s.r.l.)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Filter device (E.P.I. FilterWire, Boston Scientific Corp.)
Number of subjects: 42
Study: 11789280

Group type: EXPERIMENTAL
Intervention: Integrated laparoscopy with Chinese herbal medicine (combination group)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Chinese herbal medicine (TCM group)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Danazol (WM group)
Number of subjects: 152
Study: 9279969

Group type: EXPERIMENTAL
Intervention: Lisinopril 10-20 mg day-1
Number of subjects: 43

Group type: COMPARATOR
Intervention: Atenolol 50-100 mg day-1
Number of subjects: 43
Study: 8342402

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Droperidol 10 micrograms/kg
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Metoclopramide 0.1 mg/kg
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Droperidol 10 micrograms/kg and Metoclopramide 0.1 mg/kg
Number of subjects: 104
Study: 31677630

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no resistance training)
Number of subjects: 32
Study: 29168575

Group type: EXPERIMENTAL
Intervention: Cuffed tracheal tubes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uncuffed tracheal tubes
Number of subjects: 0
Study: 26888338

Group type: EXPERIMENTAL
Intervention: Cefoperazone-sulbactam (CS) 2 g/8 h/day, IV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Piperacillin-tazobactam (PIP-TAZO) 4.5 g/6 h/day, IV
Number of subjects: 0
Study: 24636461

Group type: EXPERIMENTAL
Intervention: DDAVP nasal spray (20mcg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 23062763

Group type: EXPERIMENTAL
Intervention: Quetiapine plus lithium/divalproex
Number of subjects: 1326

Group type: COMPARATOR
Intervention: Placebo plus lithium/divalproex
Number of subjects: 1326
Study: 19963428

Group type: EXPERIMENTAL
Intervention: Castor oil emulsion eyedrops (Allergan)
Number of subjects: 15
Study: 18354365

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 60
Study: 15725916

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gefitinib
Number of subjects: 0
Study: 12185379

Group type: EXPERIMENTAL
Intervention: Acarbose (100 to 300 mg/day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 10622312

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9117814

Group type: EXPERIMENTAL
Intervention: Amorphous hydrogel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dextranomer paste
Number of subjects: 0
Study: 1860557

Group type: EXPERIMENTAL
Intervention: Insulin infusion rate of 120 mU.m‐2.min‐1
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Insulin infusion rate of 40 mU.m‐2.m‐1
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Blood glucose lowered to 2.8 mM
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Blood glucose lowered to 2 mM
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Higher insulin infusion rate
Number of subjects: 9
Study: 6336864

Group type: EXPERIMENTAL
Intervention: 1 gm intravenous metronidazole preoperatively and five intravenous doses of 500 mg metronidazole postoperatively
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo only
Number of subjects: 72
Study: 30882953

Group type: EXPERIMENTAL
Intervention: ADPP (Pro-Kolin Advanced)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 28118538

Group type: EXPERIMENTAL
Intervention: Peficitinib 25 mg
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Peficitinib 50 mg
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Peficitinib 100 mg
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Peficitinib 150 mg
Number of subjects: 289

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study: 26649448

Group type: EXPERIMENTAL
Intervention: High-dose VM202 (n=20)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Low-dose VM202 (n=21)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo (n=11)
Number of subjects: 52
Study: 24443876

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg + MET
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo + MET
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Ongoing weight loss (regardless of treatment arm)
Number of subjects: 180
Study: 21816315

Group type: EXPERIMENTAL
Intervention: Baroreflex activation therapy (BAT)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Delayed BAT initiation (Control Group B)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 265
Study: 19008868

Group type: EXPERIMENTAL
Intervention: Catechin-rich beverage (582.8 mg of catechins per day)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (96.3 mg of catechins per day)
Number of subjects: 43
Study: 17898242

Group type: EXPERIMENTAL
Intervention: Computerized decision aid + written information
Number of subjects: 149

Group type: COMPARATOR
Intervention: Written information alone
Number of subjects: 149
Study: 15206989

Group type: EXPERIMENTAL
Intervention: CIC 400 microg once daily
Number of subjects: 19

Group type: COMPARATOR
Intervention: FP 250 microg twice daily
Number of subjects: 19
Study: 11207639

Group type: EXPERIMENTAL
Intervention: Dexamethasone (long course: 42-day tapering course)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dexamethasone (pulse course: repeatable 3-day pulse course)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dexamethasone (both treatment regimens)
Number of subjects: 40
Study: 9488624

Group type: EXPERIMENTAL
Intervention: Filgrastim 10 microg/kg/d
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Filgrastim 30 microg/kg/d
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Filgrastim 20-40 microg/kg/d
Number of subjects: 90
Study: 7848993

Group type: EXPERIMENTAL
Intervention: Orthopantomograms (OPG)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Bone scans
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: CT scans
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: MRI scans
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Direct inspection after periosteal stripping
Number of subjects: 35
Study: 3182309

Group type: EXPERIMENTAL
Intervention: Melphalan (L-PAM) and prednisone (pred) therapy for 12 weeks followed by total bone marrow irradiation (TBMI) at a dose of 1500 cGy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Total bone marrow irradiation (TBMI) at a dose of 1500 cGy
Number of subjects: 20
Study: 31038755

Group type: EXPERIMENTAL
Intervention: FMT capsules
Number of subjects: 20
Study: 27269279

Group type: EXPERIMENTAL
Intervention: Bevacizumab (1.25 mg/0.05 ml)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Mitomycin C (0.2 mg/ml)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Comparison of IOP between groups
Number of subjects: 80

Group type: COMPARATOR
Intervention: Bleb morphological features based on MBGS
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 80
Study: 25737472

Group type: EXPERIMENTAL
Intervention: Laryngeal electromyography (LEMG) of the thyroarytenoid muscles by different techniques
Number of subjects: 40
Study: 23354008

Group type: EXPERIMENTAL
Intervention: AGEs inhibitor (benfotiamine [50 mg]+pyridoxamine [50 mg]+methylcobalamin [500 µg])
Number of subjects: 30
Study: 21750558

Group type: EXPERIMENTAL
Intervention: Capecitabine-attributed skin toxicity (Cape-ST) grade 1-3
Number of subjects: 185

Group type: COMPARATOR
Intervention: Capecitabine-attributed skin toxicity (Cape-ST) grade 0
Number of subjects: 185
Study: 19831167

Group type: EXPERIMENTAL
Intervention: New toothpaste containing 8.0% arginine, calcium carbonate, and 1450 ppm fluoride as MFP
Number of subjects: 80

Group type: COMPARATOR
Intervention: Benchmark commercial desensitizing toothpaste containing 2% potassium ion, dosed as 5.0% potassium nitrate, and 1450 ppm fluoride as NaF
Number of subjects: 80
Study: 15295247

Group type: EXPERIMENTAL
Intervention: Steri Strip Skin Closures
Number of subjects: 100

Group type: COMPARATOR
Intervention: Dermabond
Number of subjects: 100
Study: 11683426

Group type: EXPERIMENTAL
Intervention: Ipriflavone (600 mg/day)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 9629989

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) - single oral dose (7 mg x kg(‐1))
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Creatine (CRE) - repeated oral doses (3 x 100 mg x kg(‐1) x day(‐1)) for 3 days
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Combination of caffeine and creatine (CAF + CRE)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 7
Study: 7930327

Group type: EXPERIMENTAL
Intervention: Geriatric evaluation and management model (assignment of a geriatrician and a social worker as the primary managing team)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Geriatric evaluation and management model
Number of subjects: 141
Study: 3048147

Group type: EXPERIMENTAL
Intervention: Intra-arterial continuous display oxygen electrode
Number of subjects: 9

Group type: COMPARATOR
Intervention: Conventional intermittent blood gas samples
Number of subjects: 9
Study: 30172659

Group type: EXPERIMENTAL
Intervention: DHA + EPA (4 g daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29659856

Group type: EXPERIMENTAL
Intervention: RCT-experimental group with alerts and access to physical abuse-specific order set
Number of subjects: 130

Group type: COMPARATOR
Intervention: RCT-control group with no alerts but manual access to order set
Number of subjects: 130

Group type: COMPARATOR
Intervention: Preintervention group with no alerts or access to order set
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Use of the physical abuse order set during the RCT
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Availability of the order set
Number of subjects: 130
Study: 26997232

Group type: EXPERIMENTAL
Intervention: Culturally tailored, nurse-led educational intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 24863156

Group type: EXPERIMENTAL
Intervention: Intensive medical management plus rigorous lifestyle intervention (LS/IMM)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: LS/IMM with Roux-en-Y gastric bypass (RYGB)
Number of subjects: 120
Study: 23174634

Group type: EXPERIMENTAL
Intervention: ACUITY-PCI risk score
Number of subjects: 2538

Group type: COMPARATOR
Intervention: GRACE and TIMI risk scores
Number of subjects: 2538
Study: 20679737

Group type: EXPERIMENTAL
Intervention: Cutting Balloon Angioplasty (CBA)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Plain Balloon Angioplasty (PBA)
Number of subjects: 224
Study: 18188803

Group type: EXPERIMENTAL
Intervention: Traditional rehabilitation approach
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Behaviour-medical rehabilitation approach
Number of subjects: 363

Group type: COMPARATOR
Intervention: Assigned approach (either traditional or behaviour-medical)
Number of subjects: 363
Study: 15855574

Group type: EXPERIMENTAL
Intervention: Insulin detemir 0.1 units/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Insulin detemir 0.2 units/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Insulin detemir 0.4 units/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Insulin detemir 0.8 units/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Insulin detemir 1.6 units/kg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Insulin detemir 0.29 units/kg
Number of subjects: 12
Study: 11935130

Group type: EXPERIMENTAL
Intervention: D2 total gastrectomy (TG)
Number of subjects: 187

Group type: COMPARATOR
Intervention: D2 total gastrectomy plus splenectomy (TGS)
Number of subjects: 187
Study: 10051050

Group type: EXPERIMENTAL
Intervention: Neoral
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sandimmune
Number of subjects: 50
Study: 7627529

Group type: EXPERIMENTAL
Intervention: Direct vision
Number of subjects: 3

Group type: COMPARATOR
Intervention: 2-D imaging
Number of subjects: 3

Group type: COMPARATOR
Intervention: 3-D imaging
Number of subjects: 3

Group type: COMPARATOR
Intervention: Electronic imaging (2-D and 3-D)
Number of subjects: 3
Study: 2186616

Group type: EXPERIMENTAL
Intervention: Oral iron supplementation (ferrous sulfate or ferrous gluconate)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 6990208

Group type: EXPERIMENTAL
Intervention: Once-a-day spironolactone therapy
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Twice-a-day spironolactone therapy
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Twice-a-day therapy
Number of subjects: 17
Study: 31469752

Group type: EXPERIMENTAL
Intervention: Fascia iliaca compartment block
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (no fascia iliaca block)
Number of subjects: 47
Study: 30612238

Group type: EXPERIMENTAL
Intervention: Palliative rehabilitation (basic offer: 2 consultations and 12-week contact possibility)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Palliative rehabilitation (group program participation)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Palliative rehabilitation (individual consultations)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Palliative rehabilitation (overall satisfaction)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Palliative rehabilitation (multidisciplinary model)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Standard oncology treatment
Number of subjects: 132
Study: 28316103

Group type: EXPERIMENTAL
Intervention: Accelerated BMD loss (n = 237)
Number of subjects: 2473

Group type: COMPARATOR
Intervention: Maintenance of BMD (n = 453)
Number of subjects: 2473

Group type: EXPERIMENTAL
Intervention: Incident hip fracture (n = 2473)
Number of subjects: 2473
Study: 26383249

Group type: EXPERIMENTAL
Intervention: Subtracting the standing oxygen cost (4.8 ± 0.4 mL·kg(‐1)·min(‐1))
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Net ES (level 4.09 ± 0.31, uphill 4.22 ± 0.37, downhill 4.16 ± 0.44 km·h(‐1))
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Gross EOTS (level 7.49 ± 0.32, downhill 7.78 ± 0.33 km·h(‐1))
Number of subjects: 11
Study: 25407539

Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Group B
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Group C
Number of subjects: 102

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 102
Study: 21953311

Group type: EXPERIMENTAL
Intervention: Supervised exercise (200 min/wk, 123 minutes average)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Unsupervised exercise (200 min/wk, 77 minutes average)
Number of subjects: 160
Study: 19021596

Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of 2.5 mg bevacizumab
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of 5.0 mg bevacizumab
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of 1.25 mg bevacizumab
Number of subjects: 29